Enasidenib Plus Azacitidine vs Azacitidine Monotherapy in mIDH2 Newly Diagnosed Acute Myeloid Leukemia

May 29-31, 2020; Online at meetings.asco.org/am
Enasidenib plus azacitidine showed significantly improved response rates compared with azacitidine alone in patients with mIDH2 newly diagnosed acute myeloid leukemia.
Format: Microsoft PowerPoint (.ppt)
File Size: 264 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

Jorge Cortes, MD, and Eunice S. Wang, MD, discuss important leukemia studies at the virtual Hematology 2020 annual meeting, as reported by Clinical Care Options (CCO).

Jorge Cortes, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: February 12, 2021 Expired: February 11, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue